A Phase 1 Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas
Latest Information Update: 01 Aug 2024
At a glance
- Drugs Milademetan (Primary)
- Indications Diffuse large B cell lymphoma; Liposarcoma; Lymphoma; Malignant melanoma; Sarcoma; Solid tumours; Synovial sarcoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Daiichi Sankyo Company; Daiichi Sankyo Inc
- 23 Mar 2023 Results assessing the safety profile and management of adverse events of milademetan from U101; NCT01877382 and MANTRA-2; NCT05012397 studies, presented at the British Sarcoma Group (BSG) Conference.
- 21 Mar 2023 According to Rain Oncology media release, a copy of the presentation materials containing data from this study can be accessed by visiting the Resources section of the Rain website after the conclusion of the presentation and will be archived on the Rain website
- 23 Jan 2023 Results published in the Rain Oncology media release.